Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02689284 |
Recruitment Status :
Completed
First Posted : February 23, 2016
Results First Posted : August 4, 2022
Last Update Posted : August 4, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer Stomach Cancer Esophageal Cancer | Biological: Margetuximab 10 mg/kg Biological: Margetuximab 15 mg Biological: Pembrolizumab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 95 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer |
Actual Study Start Date : | January 2016 |
Actual Primary Completion Date : | January 2021 |
Actual Study Completion Date : | January 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg
margetuximab administered in combination with pembrolizumab
|
Biological: Margetuximab 10 mg/kg
Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
Other Name: MGAH22 Biological: Pembrolizumab Pembrolizumab treatment is administered IV once every 21-day cycle
Other Name: MK-3475 |
Experimental: Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg
margetuximab administered in combination with pembrolizumab
|
Biological: Margetuximab 15 mg
Margetuximab treatment is administered IV once every 21-day cycle
Other Name: MGAH22 Biological: Pembrolizumab Pembrolizumab treatment is administered IV once every 21-day cycle
Other Name: MK-3475 |
- Number of Patients With Dose Limiting Toxicities [ Time Frame: 21 days ]Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab
- Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs). [ Time Frame: up to 24 months ]The number of patients that experience either an AE or a SAE during the study participation
- Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment [ Time Frame: 12 months ]Investigate the preliminary anti-tumor activity as measured by response to treatment of margetuximab when administered in combination with pembrolizumab, using conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment Using irRC Criteria [ Time Frame: 12 Months ]Investigate the preliminary anti-tumor activity, as measured by objective response rate (ORR) of margetuximab when administered in combination with pembrolizumab, using immune-related response criteria (irRC).
- Duration of Response [ Time Frame: up to 24 months ]Duration of response is calculated at the time from CR or PR to relapse or cancer progression.
- Overall Survival (OS) [ Time Frame: 24 Months ]The median length of time between first dose of study medication and death from any cause.
- Progression Free Survival (PFS) [ Time Frame: 24 Months ]The interval between the first dose of study medication and progression of disease or death from any cause.
- Change From Baseline in Pharmacodynamic Markers in Whole Blood [ Time Frame: from first dose to the end of treatment, average about 12 months ]The planned assessment included examination of markers of T-cell activation
- Analysis of HER2 Tumor Cell Membrane Expression in Biopsy Specimens Before and After Treatment [ Time Frame: from first dose to the end of treatment, average 12 months. ]
- Number of Patients Who Develop Treatment-emergent Anti-drug Antibodies to Margetuximab (Immunogenicity) [ Time Frame: Assessed Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Day 1 of every odd cycle, and end of treatment visit, average 12 months ]
- Maximum Concentration of Margetuximab at Steady State [ Time Frame: At end of infusion on Cycle 1, Day 1. Cycle 2, Day 1; Cycle 3, Days 1 and 2; Cycle 5 Day 1, Cycle 7 Day 1, and end of treatment visit, average 12 months ]Measurement of PK characteristics is limited to margetuximab. No analysis of pembrolizumab was conducted.
- Area Under the Concentration Time Curve at Steady State (AUC ss) [ Time Frame: Predose and at end of infusion on Cycle 1, Days 1, 2 and 8: Cycle 2, Day 1; Cycle 3, Days 1 and 2; Cycle 5 Day 1, Cycle 7 Day 1, and end of treatment visit, average 12 months ]AUC is a mathematical calculation that describes the variation in drug concentration in the blood over time.
- Clearance [ Time Frame: Predose and at end of infusion on Cycle 1, Days 1, 2 and 8: Cycle 2, Day 1; Cycle 3, Days 1 and 2; Cycle 5 Day 1, Cycle 7 Day 1, and end of treatment visit, average 12 months. ]Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time.
- Volume of Distribution at Steady State [ Time Frame: Predose and at end of infusion on Cycle 1, Days 1, 2 and 8: Cycle 2, Day 1; Cycle 3, Days 1 and 2; Cycle 5 Day 1, Cycle 7 Day 1, and end of treatment visit average 12 months . ]The volume of distribution is related to a whether how much drug is distributed to body tissues, or remains in the bloodstream.
- Terminal Half-life [ Time Frame: Predose and at end of infusion on Cycle 1, Days 1, 2 and 8: Cycle 2, Day 1; Cycle 3, Days 1 and 2; Cycle 5 Day 1, Cycle 7 Day 1, and end of treatment visit average 12 months . ]Terminal half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed written informed consent.
- Age ≥ 18 years old (or minimum age based upon local regulations)
- Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will include only gastric cancer patients with 3+ HER2 positivity.
- HER2+ as 3+ (as defined in AJCC staging manual 8th edition) by IHC or in-situ hybridation (ISH) amplified.
- Have received prior treatment with trastuzumab.
- Have received treatment with at least one or more lines of cytotoxic chemotherapy in the metastatic setting.
- Resolution of chemotherapy, immunotherapy or radiation-related toxicities.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
- Measurable disease as per RECIST 1.1 criteria.
Exclusion Criteria:
- Patients with symptomatic central nervous system (CNS) metastases.
- Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.
- History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
- Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 3 weeks prior to the initiation of study drug.
- Treatment with radiation therapy within 3 weeks prior to the initiation of study drug administration.
- Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.
- History of clinically-significant cardiovascular disease.
- Clinically-significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.
- History of (non-infectious) pneumonitis that required steroids or presence of active pneumonitis
- Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.
- Evidence of active viral, bacterial, or systemic fungal infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02689284
Study Director: | Stephen L Eck, M.D., PhD | MacroGenics |
Documents provided by MacroGenics:
Responsible Party: | MacroGenics |
ClinicalTrials.gov Identifier: | NCT02689284 |
Other Study ID Numbers: |
CP-MGAH22-05 |
First Posted: | February 23, 2016 Key Record Dates |
Results First Posted: | August 4, 2022 |
Last Update Posted: | August 4, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Pembrolizumab |
Margetuximab Antibodies, Monoclonal Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Immunologic Factors Physiological Effects of Drugs |